Clinical Trial Update: IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating an IL-2 expressing, attenuated Salmonella Typhimurium for unresectable hepatic spread in liver cancer patients has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cancer
• Hepatocellular Carcinoma
• Liver Cancer
• Liver Neoplasms

Drugs mentioned

• IL-2 expressing, attenuated Salmonella Typhimurium (interleukin-2 expressing attenuated Salmonella Typhimurium)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Cancer of the Liver, Liver Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-07-20